The effect of stable macromolecular complexes of ionic polyphosphazene on HIV Gag antigen and on activation of human dendritic cells and presentation to T-cells

Biomaterials

Volumn 35, Issue 31, 2014, Pages 8876-8886

  Palmer, Christine D ^a,b,d   Ninković, Jana ^a,b,f   Prokopowicz, Zofia M ^a,b   Mancuso, Christy J ^a   Marin, Alexander ^c   Andrianov, Alexander K ^c,e   Dowling, David J ^a,b   Levy, Ofer ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Apogee Technology Inc   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

^f 3M COMPANY   (United States)

Author keywords

Adjuvant; Dendritic cell; Neonate; Newborn; T cell; Vaccine

Indexed keywords

ANTIGENS; CELL DEATH; CHEMICAL ACTIVATION; POLYELECTROLYTES; T-CELLS; VACCINES;

ADJUVANT; DENDRITIC CELLS; DENDRITIC CELLS (DCS); HUMAN DENDRITIC CELLS; MACROMOLECULAR COMPLEXES; NEONATE; NEWBORN; NON-COVALENT INTERACTION;

DISEASES;

ALUMINUM POTASSIUM SULFATE; CD4 ANTIGEN; GAG PROTEIN; POLYELECTROLYTE; POLY[DI(CARBOXYLATOPHENOXY) PHOSPHAZENE]; UNCLASSIFIED DRUG; ALUMINUM SULFATE; IMMUNOLOGICAL ADJUVANT; ORGANOPHOSPHORUS COMPOUND; POLY(PHOSPHAZENE); POLYMER; RECOMBINANT PROTEIN;

ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFECT; DRUG FORMULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; INTERNALIZATION; NUCLEOTIDE SEQUENCE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; T LYMPHOCYTE; UPREGULATION; VACCINE PRODUCTION; ADULT; CELL CULTURE; CELLULAR IMMUNITY; DRUG EFFECTS; IMMUNOLOGY; INFANT;

ANIMALIA;

ADJUVANTS, IMMUNOLOGIC; ADULT; ALUM COMPOUNDS; ANTIGEN PRESENTATION; CELLS, CULTURED; DENDRITIC CELLS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HUMANS; IMMUNITY, CELLULAR; INFANT; ORGANOPHOSPHORUS COMPOUNDS; POLYMERS; RECOMBINANT PROTEINS;

EID: 84905504230     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.06.043     Document Type: Article

References (48)

1. Levy O., Goriely S., Kollmann T.R. Immune response to vaccine adjuvants during the first year of life. Vaccine 2013, 31(21):2500-2505.
2. Rappuoli R., Mandl C.W., Black S., De Gregorio E. Vaccines for the twenty-first century society. Nat Rev Immunol 2011, 11(12):865-872.
3. Adrianov A.K. Polyphosphazene vaccine delivery vehicles - state of development and perspectives 2009, John Wiley & Sons, Hoboken, NJ. A.K. Andrianov (Ed.).
4. Andrianov A.K., DeCollibus D.P., Gillis H.A., Kha H.H., Marin A., Prausnitz M.R., et al. Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization. Proc Natl Acad Sci U S A 2009, 106(45):18936-18941.
5. Andrianov A.K., Decollibus D.P., Marin A., Webb A., Griffin Y., Webby R.J. PCPP-formulated H5N1 influenza vaccine displays improved stability and dose-sparing effect in lethal challenge studies. J Pharm Sci 2011, 100(4):1436-1443.
6. Mutwiri G., Babiuk L.A. Potential of polyphosphazenes in modulating vaccine-induced immune responses: II. Investigation in large animals. Polyphosphazenes for biomedical applications 2009, John Wiley & Sons. A.K. Andrianov (Ed.).
7. Mutwiri G., Benjamin P., Soita H., Townsend H., Yost R., Roberts B., et al. Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine 2007, 25(7):1204-1213.
8. Payne L.G., Jenkins S.A., Woods A.L., Grund E.M., Geribo W.E., Loebelenz J.R., et al. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine 1998, 16(1):92-98.
9. Bouveret Le Cam N.N., Ronco J., Francon A., Blondeau C., Fanget B. Adjuvants for influenza vaccine. Res Immunol 1998, 149(1):19-23.
10. Ison M.G., Mills J., Openshaw P., Zambon M., Osterhaus A., Hayden F. Current research on respiratory viral infections: fourth International Symposium. Antiviral Res. 2002, 55(2):227-278.
11. Andrianov A.K., Marin A., Roberts B.E. Polyphosphazene polyelectrolytes: a link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity. Biomacromolecules 2005, 6(3):1375-1379.
12. Andrianov A.K., Chen J., Payne L.G. Preparation of hydrogel microspheres by coacervation of aqueous polyphosphazene solutions. Biomaterials 1998, 19(1-3):109-115.
13. Marin A., Decollibus D.P., Andrianov A.K. Protein stabilization in aqueous solutions of polyphosphazene polyelectrolyte and non-ionic surfactants. Biomacromolecules 2010, 11(9):2268-2273.
14. Frokjaer S., Otzen D.E. Protein drug stability: a formulation challenge. Nat Rev Drug Discov 2005, 4(4):298-306.
15. Clapp T., Siebert P., Chen D., Jones Braun L. Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability. J Pharm Sci 2011, 100(2):388-401.
16. Amorij J.P., Huckriede A., Wilschut J., Frijlink H.W., Hinrichs W.L. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res 2008, 25(6):1256-1273.
17. Luykx D.M., Casteleijn M.G., Jiskoot W., Westdijk J., Jongen P.M. Physicochemical studies on the stability of influenza haemagglutinin in vaccine bulk material. European journal of pharmaceutical sciences. Off J Eur Fed Pharm Sci 2004, 23(1):65-75.
18. Reed S.G., Orr M.T., Fox C.B. Key roles of adjuvants in modern vaccines. Nat Med 2013, 19(12):1597-1608.
19. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33(4):492-503.
20. Marichal T., Ohata K., Bedoret D., Mesnil C., Sabatel C., Kobiyama K., et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med 2011, 17(8):996-1002.
21. Kool M., Willart M.A., van Nimwegen M., Bergen I., Pouliot P., Virchow J.C., et al. An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. Immunity 2011, 34(4):527-540.
22. Acunzo J., Katsogiannou M., Rocchi P. Small heat shock proteins HSP27 (HspB1), alphaB-crystallin (HspB5) and HSP22 (HspB8) as regulators of cell death. Int J Biochem Cell Biol 2012, 44(10):1622-1631.
23. Flach T.L., Ng G., Hari A., Desrosiers M.D., Zhang P., Ward S.M., et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med 2011, 17(4):479-487.
24. Levitz S.M., Golenbock D.T. Beyond empiricism: informing vaccine development through innate immunity research. Cell 2012, 148(6):1284-1292.
25. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007, 7(5):379-390.
26. Marodi L. Innate cellular immune responses in newborns. Clin Immunol 2006, 118(2-3):137-144.
27. Sanchez-Schmitz G., Levy O. Development of newborn and infant vaccines. Sci Transl Med 2011, 3(90):90ps27.
28. Dowling D.J., Levy O. Ontogeny of early life immunity. Trends Immunol 2014, 35(7):299-310.
29. Gamble T.R., Yoo S., Vajdos F.F., von Schwedler U.K., Worthylake D.K., Wang H., et al. Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein. Science 1997, 278(5339):849-853.
30. Andrianov A.K., Svirkin Y.Y., LeGolvan M.P. Synthesis and biologically relevant properties of polyphosphazene polyacids. Biomacromolecules 2004, 5(5):1999-2006.
31. Baldi L., Hacker D.L., Meerschman C., Wurm F.M. Large-scale transfection of mammalian cells. Methods Mol Biol 2012, 801:13-26.
32. Dowling D.J., Tan Z., Prokopowicz Z.M., Palmer C.D., Matthews M.A., Dietsch G.N., et al. The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes. PLoS One 2013, 8(3):e58164.
33. Palmer C.D., Rahman F.Z., Sewell G.W., Ahmed A., Ashcroft M., Bloom S.L., et al. Diminished macrophage apoptosis and reactive oxygen species generation after phorbol ester stimulation in Crohn's disease. PloS one 2009, 4(11):e7787.
34. + T cells: HIV antigen presentation, T-cell activation, and viral transfer. Blood 2006, 108(5):1643-1651.
35. Bustin S.A. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000, 25(2):169-193.
36. Philbin V.J., Dowling D.J., Gallington L.C., Cortes G., Tan Z., Suter E.E., et al. Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways. J Allergy Clin Immunol 2012, 130(1):195-204 e9.
37. Andrianov A.K., Le Golvan M.P. Characterization of poly[di(carboxylatophenoxy)-phosphazene] by an aqueous gel permeation chromatography. J Appl Polym Sci 1996, 60(12):2289-2295.
38. Jaworski J.P., Krebs S.J., Trovato M., Kovarik D.N., Brower Z., Sutton W.F., et al. Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells. PloS one 2012, 7(2):e31464.
39. Rappuoli R., Aderem A.A. 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 2011, 473(7348):463-469.
40. Shim D.H., Ko H.J., Volker G., Potter A.A., Mutwiri G., Babiuk L.A., et al. Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens. Vaccine 2010, 28(11):2311-2317.
41. Gilbert P.B., Chiu Y.L., Allen M., Lawrence D.N., Chapdu C., Israel H., et al. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored phase I and II clinical trials. Vaccine 2003, 21(21-22):2933-2947.
42. Manolova V., Flace A., Bauer M., Schwarz K., Saudan P., Bachmann M.F. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008, 38(5):1404-1413.
43. Agnandji S.T., Lell B., Fernandes J.F., Abossolo B.P., Methogo B.G., Kabwende A.L., et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012, 367(24):2284-2295.
44. Agnandji S.T., Lell B., Soulanoudjingar S.S., Fernandes J.F., Abossolo B.P., Conzelmann C., et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011, 365(20):1863-1875.
45. Miao E.A., Rajan J.V., Aderem A. Caspase-1-induced pyroptotic cell death. Immunol Rev 2011, 243(1):206-214.
46. Rathinam V.A., Vanaja S.K., Fitzgerald K.A. Regulation of inflammasome signaling. Nat Immunol 2012, 13(4):333-342.
47. Breloer M., Dorner B., More S.H., Roderian T., Fleischer B., von Bonin A. Heat shock proteins as "danger signals": eukaryotic Hsp60 enhances and accelerates antigen-specific IFN-gamma production in T cells. Eur J Immunol 2001, 31(7):2051-2059.
48. Rovere P., Vallinoto C., Bondanza A., Crosti M.C., Rescigno M., Ricciardi-Castagnoli P., et al. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 1998, 161(9):4467-4471.